Literature DB >> 30350021

Expression profiles and prognostic value of miRNAs in retinoblastoma.

Lara Elis Alberici Delsin1, Karina Bezerra Salomao1, Julia Alejandra Pezuk2, Maria Sol Brassesco3.   

Abstract

Current cure rates for retinoblastoma (RB) are very high in developed countries. Nonetheless, in less privileged places worldwide, delayed diagnosis and refusal to adhere to treatment still endure an obstacle to improve overall patient survival. Thus, the access to consistent biomarkers for diagnosis at an earlier stage may facilitate treatment and improve outcomes. Over recent years, much attention has been focused on miRNAs, key post-transcriptional regulators that when altered, largely contribute to carcinogenesis and tumor progression. Many of the ~ 2500 microRNAs described in humans have shown differential expression profiles in tumors. In this review, we summarize current data about the roles of miRNAs in RB along with their value as diagnostic/prognostic factors using electronic databases such as PubMed. We reviewed the importance of miRNA in RB biology and discussed their implications in clinic intervention. Several miRNAs have pointed out reliable diagnostic and prognostic molecular biomarkers. The emergence of targeted therapies has significantly improved cancer treatment. In the near future, the modulation of miRNAs will represent a good treatment strategy.

Entities:  

Keywords:  Cancer; Children; Retinoblastoma; Review; Solid tumor; miRNA

Mesh:

Substances:

Year:  2018        PMID: 30350021     DOI: 10.1007/s00432-018-2773-7

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  111 in total

Review 1.  Challenges and obstacles of ocular pharmacokinetics and drug delivery.

Authors:  Arto Urtti
Journal:  Adv Drug Deliv Rev       Date:  2006-09-26       Impact factor: 15.470

2.  Using expression profiling data to identify human microRNA targets.

Authors:  Jim C Huang; Tomas Babak; Timothy W Corson; Gordon Chua; Sofia Khan; Brenda L Gallie; Timothy R Hughes; Benjamin J Blencowe; Brendan J Frey; Quaid D Morris
Journal:  Nat Methods       Date:  2007-11-18       Impact factor: 28.547

Review 3.  RNAi therapeutics: an update on delivery.

Authors:  Thu Nguyen; Ellen M Menocal; Jens Harborth; Johannes H Fruehauf
Journal:  Curr Opin Mol Ther       Date:  2008-04

4.  Most mammalian mRNAs are conserved targets of microRNAs.

Authors:  Robin C Friedman; Kyle Kai-How Farh; Christopher B Burge; David P Bartel
Journal:  Genome Res       Date:  2008-10-27       Impact factor: 9.043

5.  Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis.

Authors:  Jian-Jun Zhao; Juhua Yang; Jianhong Lin; Nan Yao; Yihua Zhu; Jianlong Zheng; Jianhua Xu; Jin Q Cheng; Jian-Yin Lin; Xu Ma
Journal:  Childs Nerv Syst       Date:  2008-09-26       Impact factor: 1.475

6.  Inhibiting survivin expression enhances TRAIL-induced tumoricidal activity in human hepatocellular carcinoma via cell cycle arrest.

Authors:  Song-Qing He; Hasibur Rehman; Ming-Guang Gong; Yong-Zhong Zhao; Zhi-Yong Huang; Chang-Hai Li; Wan-Guang Zhang; Xiao-Ping Chen
Journal:  Cancer Biol Ther       Date:  2007-05-16       Impact factor: 4.742

Review 7.  Retinoblastoma: review of current management.

Authors:  Murali Chintagumpala; Patricia Chevez-Barrios; Evelyn A Paysse; Sharon E Plon; Richard Hurwitz
Journal:  Oncologist       Date:  2007-10

Review 8.  Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.

Authors:  Brian G Short
Journal:  Toxicol Pathol       Date:  2008-01       Impact factor: 1.902

9.  Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.

Authors:  Charles H Lawrie; Shira Gal; Heather M Dunlop; Beena Pushkaran; Amanda P Liggins; Karen Pulford; Alison H Banham; Francesco Pezzella; Jacqueline Boultwood; James S Wainscoat; Christian S R Hatton; Adrian L Harris
Journal:  Br J Haematol       Date:  2008-03-03       Impact factor: 6.998

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more
  7 in total

1.  MicroRNA‑936 inhibits the malignant phenotype of retinoblastoma by directly targeting HDAC9 and deactivating the PI3K/AKT pathway.

Authors:  Lishuai Xu; Weidong Li; Qian Shi; Minfeng Wang; Heng Li; Xiaoli Yang; Junjun Zhang
Journal:  Oncol Rep       Date:  2020-01-09       Impact factor: 4.136

2.  Identification of Epigenetically Modified Hub Genes and Altered Pathways Associated With Retinoblastoma.

Authors:  Aditi Karmakar; Md Maqsood Ahamad Khan; Nidhi Kumari; Nalini Devarajan; Senthil Kumar Ganesan
Journal:  Front Cell Dev Biol       Date:  2022-03-10

Review 3.  Applications of Non-Coding RNAs in Patients With Retinoblastoma.

Authors:  Daniel Fernandez-Diaz; Cristina Rodriguez-Vidal; Paula Silva-Rodríguez; Laura Paniagua; María José Blanco-Teijeiro; María Pardo; Antonio Piñeiro; Manuel Bande
Journal:  Front Genet       Date:  2022-03-31       Impact factor: 4.599

4.  microRNA-362-3p targets USP22 to retard retinoblastoma growth via reducing deubiquitination of LSD1.

Authors:  Junbo Rong; Zhigang Li; Limin Xu; Lijuan Lang; Guangying Zheng
Journal:  Cell Cycle       Date:  2021-01-21       Impact factor: 4.534

5.  Long noncoding RNA SNHG14 promotes the aggressiveness of retinoblastoma by sponging microRNA‑124 and thereby upregulating STAT3.

Authors:  Xiaowen Sun; Hui Shen; Shubin Liu; Jing Gao; Shuyan Zhang
Journal:  Int J Mol Med       Date:  2020-03-20       Impact factor: 4.101

6.  microRNA-181a-5p impedes the proliferation, migration, and invasion of retinoblastoma cells by targeting the NRAS proto-oncogene.

Authors:  Ming Ouyang; Guiqin Liu; Cheng Xiong; Jing Rao
Journal:  Clinics (Sao Paulo)       Date:  2022-03-24       Impact factor: 2.365

7.  Bioinformatics analysis of multi-omics data identifying molecular biomarker candidates and epigenetically regulatory targets associated with retinoblastoma.

Authors:  Yuyang Zeng; Tao He; Juejun Liu; Zongyuan Li; Feijia Xie; Changzheng Chen; Yiqiao Xing
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.